Heinzelmann, F. and Bethge, W. and Beelen, D. W. and Engelhard, M. and Kroeger, N. and Dreger, P. and Niederwieser, D. and Finke, J. and Bunjes, D. and Tischer, J. and Kobbe, G. and Holler, E. and Bornhaeuser, M. and Stelljes, M. and Baurmann, H. and Mueller, A. and Haubitz, I. and Schrezenmeier, H. and Mueller, C. and Ottinger, H. (2016) Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. BONE MARROW TRANSPLANTATION, 51 (5). pp. 654-662. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim of this study was to identify subgroups of FL patients who benefit from HCT. The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients who received HCT for FL between 1998 and 2008 were extracted from the database of the German Registry 'DRST'. Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2- and 5-year overall survivals (OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age <= 42 years and TBI-based conditioning in treatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatment-sensitive disease and limited chronic GvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age >= 55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors <= 42 years should be preferred if available.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NON-HODGKIN-LYMPHOMA; LOW-GRADE LYMPHOMA; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; AUTOLOGOUS TRANSPLANTATION; INDOLENT LYMPHOMA; IBRITUMOMAB TIUXETAN; OBINUTUZUMAB GA101; MALIGNANT-LYMPHOMA; UNRELATED DONOR; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Mar 2019 10:43 |
| Last Modified: | 25 Mar 2019 10:43 |
| URI: | https://pred.uni-regensburg.de/id/eprint/2999 |
Actions (login required)
 |
View Item |
